Aurobindo Pharma stock hits a 52-week high for 3rd day in a row after its US subsidiary gets US FDA approval for Ryzneuta

Aurobindo Pharma Share Price: Aurobindo Pharma shares hit a 52-week high of Rs 1,035.20 each on BSE on Wednesday (November 22) after its US-based subsidiary-Evive Biotech- gets the US FDA approval for Ryzneuta (Efbemalenograstim alfa Injection) for chemotherapy-induced neutropenia (CIN). 

The Aurobindo Pharma stock was trading 0.38 per cent higher, or Rs 3.90, at Rs 1030.65, at 10:08 am on Wednesday. 

"Evive Biotech and Acrotech Biopharma Announce FDA Approval of Ryzneuta™ (Efbemalenograstim alfa Injection) for ChemotherapyInduced Neutropenia (CIN)
-Ryzneuta™ is the first non-pegylated granulocyte colony-stimulating factor approved by both the US Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA) for treatment for CIN," Aurobindo Pharma said ina BSE filing on Wednesday. 

Aurobindo Pharma shares have been performing well for some time as they also hit a 52-week high on Tuesday and Monday as well.